According to a separate study lasting a total of 2 years, the weight loss actually remains: In the STEP 5 trial, adults with overweight and obesity treated with weekly semaglutide subcutaneous injections lost an average of more than 15% of their body weight from baseline through 104 weeks, compared with the placebo groups less than 3% weight loss
Am J Pathol 160(3):9851000 Baluk P et al (2003) Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors
Importantly, no serious adverse events have been documented in over 100 preclinical studies (Sikiric et al., 2016)
Muscles burn more calories at rest than fat, so increasing muscle mass accelerates fat loss naturally
Unlike GLP-1 medications, many of today's trending peptides havent been studied in large human trials
If the pharmacy cannot provide appropriate documentation or verification of quality standards, consider this a significant safety concern warranting discussion with your healthcare provider about alternative sources